Lupin has been reportedly looking to demerge its API business, Glenmark Pharma is looking to sell Glenmark Life Sciences as well. Why? Forbes India explains
Recently, news reports said that pharma giant Lupin might be looking to spin off its active pharmaceutical ingredient (API) vertical. Whether it would be listed as a separate entity or sold off is yet to be seen. Lupin’s shares hit a new 52-week high after reports of the potential demerger were published. This is soon after Glenmark Pharma announced plans to sell its API business. In May 2019, a new entity was set up for the API business and in August 2021 it was listed as Glenmark Life Sciences. Sekhmet Pharmaventures and the Nirma group are reportedly competing to buy the subsidiary. Additionally, experts reckon that other pharma companies such as Aurobindo Pharma have also hinted at looking to separate their API verticals in the next few years.